Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 11/20 | 0.55 |
| ▸ | KCNK9 | Q9NPC2 | 10/20 | 0.55 |
| ▸ | MEN1 | O00255 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 2/20 | 0.48 |
| ▸ | NT5E | P21589 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2286573 | 0.87 | NPC1 (0.60) | KCNK3KCNK9MEN1KMT2APOLB | |
| Formic Acid SCHEMBL2285017 | 0.84 | NPC1 (0.55) | KCNK3KCNK9MEN1KMT2APOLB | |
| SCHEMBL259666 | 0.76 | KCNK3 (0.87) | KCNK3KCNK9MEN1KMT2APOLB | |
| SCHEMBL30608967 | 0.76 | KCNK3 (0.87) | KCNK3KCNK9MEN1KMT2APOLB | |
| SCHEMBL13760913 | 0.75 | NPC1 (0.58) | KCNK3KCNK9MEN1KMT2APOLB | |
| SCHEMBL21377436 | 0.73 | KCNK3 (0.68) | KCNK3KCNK9MEN1KMT2APOLB | |
| SCHEMBL19491385 | 0.72 | KCNK3 (0.85) | KCNK3KCNK9MEN1KMT2APOLB | |
| SCHEMBL13825338 | 0.72 | BACE1 (0.52) | BACE1 | |
| SCHEMBL4253897 | 0.71 | KCNK3 (0.93) | KCNK3KCNK9MEN1KMT2APOLB | |
| SCHEMBL10155223 | 0.71 | BACE1 (0.72) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009103626-A1 | 4, 5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-27 | — | — | WO | disclosed |
| US-20090209529-A1 | 4,5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-20 | — | — | US | disclosed |
| US-20090209529-A1 | 4,5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209529-A1 | 4,5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES | BACE2, BACE1, PSEN2 | KCNK3 2865/4885KCNK9 2891/4885MEN1 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.